The therapeutic potential of Nrf2 activators for EBS

Oxidative Stress in Fragile Skin

Epidermolysis bullosa (EB) encompasses a group of rare inherited disorders where skin and mucous membranes blister and tear from minimal trauma. Epidermolysis bullosa simplex (EBS), arising from mutations in keratin genes, is the most prevalent subtype and typically less severe than dystrophic or junctional forms, yet it still imposes chronic pain, wound care burdens, and risks of infection or scarring.

Oxidative stress plays a key role in worsening tissue fragility and delaying healing in EB. Reactive oxygen species accumulate in fragile keratinocytes, amplifying inflammation and damage in already vulnerable skin. The Nrf2 pathway, a master regulator of cellular antioxidant responses, counters this by upregulating protective enzymes and reducing inflammation.

Interest in Nrf2 activators for EBS stems from their potential to bolster these defenses without directly correcting genetic defects. Compounds like sulforaphane have shown preclinical promise in related keratin disorders by inducing protective keratins and mitigating blistering. A 2025 review on antioxidant therapies for EB management underscores this direction, positioning Nrf2 modulation as a possible adjunct or standalone approach amid limited options.

The timing reflects broader momentum in EB research. Gene therapies such as Zevaskyn (approved 2025 for recessive dystrophic EB) and Vyjuvek (available since 2023) target severe subtypes by addressing collagen deficiencies. These successes, alongside repurposing efforts for common skin drugs in EB trials starting in 2026, heighten focus on complementary strategies for milder forms like EBS, where oxidative damage is a prominent driver.

Non-obvious tensions include the challenge of translating Nrf2 activation safely—overstimulation risks off-target effects seen in other diseases—while balancing costs against the small patient population. Inaction leaves EBS patients reliant on symptomatic wound care, with lifelong impacts on mobility, quality of life, and secondary complications like skin cancers in chronic wounds.